COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00458835
Recruitment Status : Completed
First Posted : April 11, 2007
Last Update Posted : December 2, 2016
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to compare the systemic des-ciclesonide exposure of OMNARIS™ (ciclesonide) nasal spray, ciclesonide HFA nasal aerosol, and orally inhaled ciclesonide HFA-metered-dose inhaler (MDI). The administration of the study medication will be as follows: three single doses, separated by a wash-out period. The study will provide further data on the safety and tolerability of ciclesonide.

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Drug: Ciclesonide Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Single-dose, 3-period Crossover, Pharmacokinetic Study Designed to Compare the Systemic Des-ciclesonide Exposure of OMNARIS™ (Ciclesonide) Nasal Spray, Ciclesonide HFA Nasal Aerosol, and Orally Inhaled Ciclesonide
Study Start Date : April 2007
Actual Primary Completion Date : April 2008
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Ciclesonide

Primary Outcome Measures :
  1. To compare the systemic exposure to des-ciclesonide with OMNARIS™ (ciclesonide nasal spray), and ciclesonide HFA nasal aerosol and orally inhaled ciclesonide.

Secondary Outcome Measures :
  1. Pharmacokinetic parameters, safety and tolerability of ciclesonide will also be assessed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Written informed consent and HIPAA
  • Body weight as indicate by a Body Mass Index (BMI) between ≥ 18 and ≤ 28 kg/m², and a body weight >50 kg
  • General good health
  • Ability to use oral inhaler

Main Exclusion Criteria:

  • Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of safe contraception in pre-menopausal women
  • Participation in any investigational drug trial within the 30 days before Screening Visit and thereafter
  • History or current clinically relevant allergies or idiosyncrasy to drugs or food
  • History of allergic reactions to any corticosteroids including ciclesonide or any excipients of the formulations
  • Any contraindication to nasally administered corticosteroids
  • History of a respiratory infection or disorder [including, but not limited to bronchitis, pneumonia, acute or chronic sinusitis, flu, severe acute respiratory syndrome (SARS)] within the 30 days before Screening Visit, or development of a respiratory infection during the Screening Period
  • History or current evidence of any other relevant allergic, cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, metabolic, neurological, psychiatric, or other disease within the last 2 years
  • Non-vaccinated exposure to or active infection with, chickenpox or measles within the 21 days preceding Screening Visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00458835

Layout table for location information
United States, Texas
Austin, Texas, United States
Sponsors and Collaborators
Layout table for investigator information
Study Director: AstraZeneca AstraZeneca AstraZeneca

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AstraZeneca Identifier: NCT00458835    
Other Study ID Numbers: BY9010/M1-422
First Posted: April 11, 2007    Key Record Dates
Last Update Posted: December 2, 2016
Last Verified: September 2016
Keywords provided by AstraZeneca:
Allergic rhinitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Allergic Agents